Repeated Bout Effect i Neuromuscular Diseases

Myopathy Clinical Trial

Official title:

Repeated Bout Effect i Neuromuscular Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05599568
• Other study ID #: P-2022-168
• Status: Recruiting
• Phase: N/A
• Start date: May 15, 2022
• Est. completion date: May 30, 2025

Study information

• Verified date: April 2024
• Source: Rigshospitalet, Denmark
• Contact: Mads Stemmerik, MD
• Phone: +4535456126
• Email: mads.peter.godtfeldt.stemmerik[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The repeated bout effect (RBE) refers to the adaptation whereby a single bout of eccentric exercise protects against muscle damage from subsequent eccentric bouts. This effect has been shown in many muscle groups using both serum biomarkers, muscle soreness and imaging techniques. Though the effect is well described in healthy, it has never been studied in patients with neuromuscular diseases (NMDs).

In healthy, the RBE is only described using eccentric exercise, but unlike healthy persons, patients with NMDs can experience significant muscle damage with concentric exercise. This raises the question, if patients with NMDs could also show RBE when performing concentric exercise.

Description:

The repeated bout effect (RBE) refers to the adaptation whereby a single bout of eccentric exercise protects against muscle damage from subsequent eccentric bouts. This effect has been shown in many muscle groups using both serum biomarkers, muscle soreness and imaging techniques. Though the effect is well described in healthy, it has never been studied in patients with neuromuscular diseases (NMDs).

NMDs are a common term for diseases that affect the muscles by disease processes in the motor neuron, peripheral nerve, neuromuscular junction or the muscles. The diseases can cause symptoms such as muscle weakness, muscle fatigue and sometimes muscle pain and varying degrees of physical disability. As the mechanisms for disease varies among NMDs, it is likely that some patients will experience RBE in a similar fashion to healthy, while others may not.

Recent years have shown significant breakthrough in the treatment development for various NMDs, and many of these treatments are currently or will soon be evaluated in clinical trials. As many trials will use exercise to evaluate treatment effect, it is vital to understand whether a single bout of exercise in itself provides a protective effect on the muscles of patients with NMDs.

In healthy, the RBE is only described using eccentric exercise, but unlike healthy persons, patients with NMDs can experience significant muscle damage with concentric exercise. This raises the question, if patients with NMDs could also show RBE when performing concentric exercise.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: May 30, 2025
• Est. primary completion date: January 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age > 18 years

• The ability to complete the exercise challenge

• No concurrent medical condition that could interfere with interpretation of the results

• Molecular diagnosis of the specific condition in specified patient groups or healthy control

• No active muscle injury on the test day (caused by recent exercise, seizures, trauma, etc.)

Exclusion Criteria:

• Cardiac or pulmonary disease contraindicating peak exercise testing or strenuous exercise defined as NYHA-class III-IV

• Veins that are too difficult to puncture for blood sampling, evaluated by the investigator

• Severe muscle weakness, that prevents the subject completing the exercise test, evaluated by the investigator

Related Conditions & MeSH terms

• Myopathy
• Neuromuscular Diseases

Intervention

Other:
• Exercise
Either concentric or excentric exercise

Locations

Country	Name	City	State
Denmark	Neuromuscular Research Unit, 3342	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Mads Peter Godtfeldt Stemmerik

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Delta CK	Change in peak kreatine kinase following first and second exercise bout.	1 month